Kieran is a MRes graduate who has previously worked in a COVID laboratory. He has joined the Fibrosis team to perform High Throughput Screenings to find drugs for the prevention of fibrosis.
Kieran obtained his BSc Biochemistry and more recently his MRes Cancer Biology degree at Nottingham Trent University in 2021, where his project investigated the role of a long non-coding NA in DNA damage and cell survival. At the start of 2022 he was performing COVID and variant detection using NGS, until he began his job at ARU in August 2022 with the fibrosis team. The team is currently collaborating with AstraZeneca and Kieran is leading the phenotypic screening of their annotated compound library.